Spasovski Miroslav S, Simjanovska Liljana J, Taleski Vaso, Petrova Nada, Lazetic Liljana, Popeska Zaneta, Gaydos Charlotte A, Quinn Thomas C, Efremov Georgi D
Research Centre for Genetic Engineering and Biotechnology, Macedonian Academy of Sciences and Arts, 1000 Skopje, Republic of Macedonia.
J Eur Acad Dermatol Venereol. 2005 Jul;19(4):427-30. doi: 10.1111/j.1468-3083.2005.01204.x.
Noninvasive urine screening for Chlamydia trachomatis infections offers a valuable public health tool, that could be of vast importance in Chlamydia control programs.
The goal was to determine the prevalence of C. trachomatis infections among a sexually active population, to define the epidemiological factors associated with it, and to develop potential selective screening strategies among asymptomatic individuals in the Republic of Macedonia, using a highly sensitive and specific DNA amplification method for C. trachomatis.
A total of 1435 urine samples, divided into two main groups: asymptomatic individuals (n = 1210) and symptomatic patients (n = 225), were tested. Samples from the asymptomatic group were collected during routine screening programs, while the symptomatic group consisted of patients with symptoms of urogenital tract infection, attending sexually transmitted diseases (STD) clinics. The presence of C. trachomatis was determined using commercial AMPLICOR C. trachomatis Assay (Roche Diagnostic Systems, Inc., Branchburg, NJ, USA).
The prevalence of C. trachomatis infections among different groups was: recruits 0%, soldiers 0.4%, policemen 3.5%, clerks 4.6%, pregnant women 4%, and students 4.4%. The average prevalence for both groups (asymptomatic and symptomatic) was 2.3%[95% confidence interval (CI): 1.5-3.1%]. The average prevalence for the asymptomatic group was 1.6% (95% CI: 0.8-2.4%), while the average prevalence for the symptomatic group was 6.2% (95% CI: 3.1-9.3%) which were significantly different (P = 0.00003).
Testing first void urine specimens by AMPLICOR C. trachomatis assay is a highly sensitive and specific method for diagnosing C. trachomatis infections in men and women. This method provides health care workers and public health officials with a new molecular amplification assay that uses noninvasive urine specimens for population-based screening purposes. The prevalence of C. trachomatis was relatively low among asymptomatic individuals. However, selective screening strategies are highly recommended for testing the student population in the Republic of Macedonia.
沙眼衣原体感染的非侵入性尿液筛查提供了一种有价值的公共卫生工具,在衣原体控制项目中可能具有极其重要的意义。
目标是确定性活跃人群中沙眼衣原体感染的患病率,确定与之相关的流行病学因素,并使用针对沙眼衣原体的高度敏感和特异的DNA扩增方法,在马其顿共和国无症状个体中制定潜在的选择性筛查策略。
共检测了1435份尿液样本,分为两个主要组:无症状个体(n = 1210)和有症状患者(n = 225)。无症状组的样本在常规筛查项目中收集,而有症状组由到性传播疾病(STD)诊所就诊的有泌尿生殖道感染症状的患者组成。使用商业AMPLICOR沙眼衣原体检测试剂盒(罗氏诊断系统公司,美国新泽西州布兰奇堡)确定沙眼衣原体的存在。
不同组中沙眼衣原体感染的患病率分别为:新兵0%,士兵0.4%,警察3.5%,职员4.6%,孕妇4%,学生4.4%。两组(无症状组和有症状组)的平均患病率为2.3%[95%置信区间(CI):1.5 - 3.1%]。无症状组的平均患病率为1.6%(95%CI:0.8 - 2.4%),而有症状组的平均患病率为6.2%(95%CI:3.1 - 9.3%),两者有显著差异(P = 0.00003)。
通过AMPLICOR沙眼衣原体检测试剂盒检测首次晨尿标本是诊断男性和女性沙眼衣原体感染的一种高度敏感和特异的方法。该方法为医护人员和公共卫生官员提供了一种新的分子扩增检测方法,该方法使用非侵入性尿液标本进行基于人群的筛查。沙眼衣原体在无症状个体中的患病率相对较低。然而,强烈建议在马其顿共和国对学生群体进行选择性筛查策略。